Paper37795644
Randomized Clinical Outcome Trials in Hypertension.
Mancia G and 1 other. Hypertension, 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Randomized Clinical Outcome Trials in Hypertension. Papers, record 37795644. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37795644
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypertension | Major topic |
| Cardiovascular Diseases | Major topic |
| Humans | |
| Antihypertensive Agents | |
| Blood Pressure |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29967041 | Does Intensive Glucose Control Cancel Out Benefits of Systolic Blood Pressure Target <120 mm Hg in Patients With Diabetes Mellitus Participating in ACCORD? | Hypertension | 2018 | https://conductscience.org/library/papers/29967041 | PubMed |
| 2 | 29372279 | Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. | Diabetologia | 2018 | https://conductscience.org/library/papers/29372279 | PubMed |
| 3 | 28858984 | Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. | J Hypertens | 2017 | https://conductscience.org/library/papers/28858984 | PubMed |
| 4 | 26414968 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. | Lancet | 2015 | https://conductscience.org/library/papers/26414968 | PubMed |
| 5 | 32507038 | Antihypertensive Treatment in Elderly Frail Patients: Evidence From a Large Italian Database. | Hypertension | 2020 | https://conductscience.org/library/papers/32507038 | PubMed |
| 6 | 36240838 | Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. | Lancet | 2022 | https://conductscience.org/library/papers/36240838 | PubMed |
| 7 | 37156253 | Evidence in favour of ambulatory blood pressure grows but gaps in knowledge remain. | Lancet | 2023 | https://conductscience.org/library/papers/37156253 | PubMed |
| 8 | 11130406 | INSIGHT and NORDIL. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study. | Lancet | 2000 | https://conductscience.org/library/papers/11130406 | PubMed |
| 9 | 4862069 | Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. | JAMA | 1967 | https://conductscience.org/library/papers/4862069 | PubMed |
| 10 | 25162203 | Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. | Blood Press | 2015 | https://conductscience.org/library/papers/25162203 | PubMed |
| 11 | 16537662 | Feasibility of treating prehypertension with an angiotensin-receptor blocker. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16537662 | PubMed |
| 12 | 10826567 | Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. | J Hypertens | 2000 | https://conductscience.org/library/papers/10826567 | PubMed |
| 13 | 1969567 | Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. | Lancet | 1990 | https://conductscience.org/library/papers/1969567 | PubMed |
| 14 | 37909131 | Target blood pressure in isolated systolic hypertension: a meta-analysis of randomized outcome trials. | J Hypertens | 2023 | https://conductscience.org/library/papers/37909131 | PubMed |
| 15 | 26551272 | A Randomized Trial of Intensive versus Standard Blood-Pressure Control. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26551272 | PubMed |
| 16 | 27195814 | Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. | JAMA | 2016 | https://conductscience.org/library/papers/27195814 | PubMed |
| 17 | 37395100 | Effect of antihypertensive treatment in isolated systolic hypertension (ISH) - systematic review and meta-analysis of randomised controlled trials. | Blood Press | 2023 | https://conductscience.org/library/papers/37395100 | PubMed |
| 18 | 34232677 | Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. | Hypertension | 2021 | https://conductscience.org/library/papers/34232677 | PubMed |
| 19 | 4914579 | Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. | JAMA | 1970 | https://conductscience.org/library/papers/4914579 | PubMed |
| 20 | 36427519 | Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes. | Lancet Diabetes Endocrinol | 2022 | https://conductscience.org/library/papers/36427519 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42453630 | Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records. | Int J Hypertens | 2026 | https://conductscience.org/library/papers/42453630 | PubMed |
| 42439476 | Pharmacist-Led Ambulatory Blood Pressure Monitoring in Community Pharmacy: An Operational Feasibility Case Series. | Turk J Pharm Sci | 2026 | https://conductscience.org/library/papers/42439476 | PubMed |
| 41892319 | Estrogen, Epigenetics, and Cardiometabolic Health: Mechanisms and Therapeutic Strategies in Postmenopausal Women. | Cells | 2026 | https://conductscience.org/library/papers/41892319 | PubMed |
| 41837912 | Trends and Predictors of Premature Termination of Cardiovascular Trials: A Systematic Review. | JACC Adv | 2026 | https://conductscience.org/library/papers/41837912 | PubMed |
| 41361568 | Empowering citizens as frontline screeners: a framework with blended learning for cardiovascular risk assessment. | Sci Rep | 2025 | https://conductscience.org/library/papers/41361568 | PubMed |
| 40397037 | Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients. | Am J Hypertens | 2025 | https://conductscience.org/library/papers/40397037 | PubMed |
| 39613355 | [Cardiovascular preventive recommendations. PAPPS 2024 thematic updates]. | Aten Primaria | 2024 | https://conductscience.org/library/papers/39613355 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37795644
GET https://conductscience.org/api/papers/v1/37795644/authors